{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T19:59:03Z","timestamp":1758052743672,"version":"3.44.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"publisher","award":["R288-2018-380","R180-2014-3360"],"award-info":[{"award-number":["R288-2018-380","R180-2014-3360"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.clinbiochem.2020.06.001","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T02:11:00Z","timestamp":1591150260000},"page":"31-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Soluble urokinase plasminogen activator receptor (suPAR) is lower in disease-free patients but cannot rule out incident disease in patients with suspected cancer"],"prefix":"10.1016","volume":"84","author":[{"given":"Line J.H.","family":"Rasmussen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kasper","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesper","family":"Eugen-Olsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten","family":"Helms","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"David","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Kjaer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Mette","family":"Lebech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gitte","family":"Kronborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"S1","key":"10.1016\/j.clinbiochem.2020.06.001_b0005","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1038\/bjc.2015.49","article-title":"Stage at diagnosis and early mortality from cancer in England","volume":"112","author":"McPhail","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"9","key":"10.1016\/j.clinbiochem.2020.06.001_b0010","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1016\/j.ejca.2013.01.025","article-title":"Evidence of increasing mortality with longer diagnostic intervals for five common cancers: A cohort study in primary care","volume":"49","author":"T\u00f8rring","year":"2013","journal-title":"Eur. J. Cancer"},{"issue":"9","key":"10.1016\/j.clinbiochem.2020.06.001_b0015","first-page":"1","article-title":"Prevalence of cancer in Danish patients referred to a fast-track diagnostic pathway is substantial","volume":"62","author":"Bislev","year":"2015","journal-title":"Dan. Med. J."},{"issue":"1","key":"10.1016\/j.clinbiochem.2020.06.001_b0020","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1186\/s12885-015-1424-5","article-title":"The Danish cancer pathway for patients with serious non-specific symptoms and signs of cancer-a cross-sectional study of patient characteristics and cancer probability","volume":"15","author":"Ingeman","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clinbiochem.2020.06.001_b0025","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.2967\/jnumed.116.175380","article-title":"Whole-body 18 F-FDG PET\/CT is superior to CT as first-line diagnostic imaging in patients referred with serious nonspecific symptoms or signs of cancer: a randomized prospective study of 200 patients","volume":"58","author":"Lebech","year":"2017","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.clinbiochem.2020.06.001_b0030","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/ijc.30732","article-title":"Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer","volume":"141","author":"Rasmussen","year":"2017","journal-title":"Int. J. Cancer"},{"issue":"24","key":"10.1016\/j.clinbiochem.2020.06.001_b0035","first-page":"7126","article-title":"Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy","volume":"60","author":"Mustjoki","year":"2000","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.clinbiochem.2020.06.001_b0040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jcla.20499","article-title":"Evaluating the value of uPAR of serum and tissue on patients with cervical cancer","volume":"26","author":"Jing","year":"2012","journal-title":"J. Clin. Lab. Anal."},{"issue":"5","key":"10.1016\/j.clinbiochem.2020.06.001_b0045","first-page":"1132","article-title":"Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer","volume":"8","author":"Riisbro","year":"2002","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.clinbiochem.2020.06.001_b0050","doi-asserted-by":"crossref","first-page":"959","DOI":"10.17219\/acem\/30817","article-title":"Soluble urokinase-type plasminogen activator receptor and Ferritin concentration in patients with advanced alimentary tract carcinoma. Relationship to localization, surgical treatment and the stage of the disease \u2013 preliminary report","volume":"23","author":"Usnarska-Zubkiewicz","year":"2014","journal-title":"Adv. Clin. Exp. Med."},{"issue":"2","key":"10.1016\/j.clinbiochem.2020.06.001_b0055","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/liv.12705","article-title":"Serum soluble urokinase plasminogen activator receptor as a screening test for the early diagnosis of hepatocellular carcinoma","volume":"35","author":"Chounta","year":"2015","journal-title":"Liver Int."},{"issue":"6","key":"10.1016\/j.clinbiochem.2020.06.001_b0060","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/ijc.29505","article-title":"The combined serum levels of miR-375 and urokinase plasminogen activator receptor are suggested as diagnostic and prognostic biomarkers in prostate cancer","volume":"137","author":"Wach","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.clinbiochem.2020.06.001_b0065","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1080\/00016489950180342","article-title":"Increased levels of urokinase receptor in plasma of head and neck squamous cell carcinoma patients","volume":"119","author":"Schmidt","year":"1999","journal-title":"Acta Otolaryngol."},{"key":"10.1016\/j.clinbiochem.2020.06.001_b0070","doi-asserted-by":"crossref","DOI":"10.1093\/carcin\/bgz033","article-title":"High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma","author":"Loosen","year":"2019","journal-title":"Carcinogenesis"},{"issue":"43","key":"10.1016\/j.clinbiochem.2020.06.001_b0075","doi-asserted-by":"crossref","first-page":"27027","DOI":"10.18632\/oncotarget.25471","article-title":"Serum levels of soluble urokinase plasminogen activator receptor (suPAR) predict outcome after resection of colorectal liver metastases","volume":"9","author":"Loosen","year":"2018","journal-title":"Oncotarget."},{"issue":"12","key":"10.1016\/j.clinbiochem.2020.06.001_b0080","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1097\/CCM.0000000000003441","article-title":"Combining national early warning score with soluble urokinase plasminogen activator receptor (suPAR) improves risk prediction in acute medical patients","volume":"46","author":"Rasmussen","year":"2018","journal-title":"Crit. Care Med."},{"issue":"5","key":"10.1016\/j.clinbiochem.2020.06.001_b0085","first-page":"871","article-title":"Prognostic role of circulating soluble uPAR in various cancers: a systematic review and meta-analysis","volume":"63","author":"Liu","year":"2017","journal-title":"Clin Lab."},{"key":"10.1016\/j.clinbiochem.2020.06.001_b0090","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/jnci\/djp335","article-title":"Use of archived specimens in evaluation of prognostic and predictive biomarkers","volume":"101","author":"Simon","year":"2009","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.clinbiochem.2020.06.001_b0095","unstructured":"The Danish Health Authority. Diagnostisk pakkeforl\u00f8b for patienter med uspecifikke symptomer p\u00e5 alvorlig sygdom, der kunne v\u00e6re kr\u00e6ft [The Cancer Patient Pathway for serious non-specific symptoms and signs of cancer] (report in Danish). 2016. https:\/\/www.sst.dk\/da\/sygdom-og-behandling\/kraeft\/pakkeforloeb\/~\/media\/3AACA5B705B44EAF84F62B9FBB16AC7A.ashx."},{"key":"10.1016\/j.clinbiochem.2020.06.001_b0100","doi-asserted-by":"crossref","unstructured":"E. Lynge, J.L. Sandegaard, M. Rebolj, The Danish National Patient Register. Scand J Public Health. 2011;39(7_suppl):30-33. doi: 10.1177\/1403494811401482.","DOI":"10.1177\/1403494811401482"},{"key":"10.1016\/j.clinbiochem.2020.06.001_b0105","doi-asserted-by":"crossref","unstructured":"M.L. Gjerstorff, The Danish Cancer Registry. Scand. J. Public Health. 2011;39(7_suppl):42-45. doi: 10.1177\/1403494810393562.","DOI":"10.1177\/1403494810393562"},{"key":"10.1016\/j.clinbiochem.2020.06.001_b0110","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4137\/BMI.S19876","article-title":"Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population","volume":"9","author":"Haupt","year":"2014","journal-title":"Biomark Insights"},{"key":"10.1016\/j.clinbiochem.2020.06.001_b0115","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.clinbiochem.2020.06.001_b0120","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/emermed-2015-205444","article-title":"Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study","volume":"33","author":"Rasmussen","year":"2016","journal-title":"Emerg. Med. J."},{"key":"10.1016\/j.clinbiochem.2020.06.001_b0125","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/CLEP.S91125","article-title":"The Danish National patient registry: a review of content, data quality, and research potential","volume":"7","author":"Schmidt","year":"2015","journal-title":"Clin. Epidemiol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2020.06.001_b0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12979-018-0141-8","article-title":"Healthy lifestyles reduce suPAR and mortality in a Danish general population study","volume":"16","author":"Haupt","year":"2019","journal-title":"Immun. Ageing"}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912020303155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912020303155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:57:16Z","timestamp":1757865436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912020303155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":26,"alternative-id":["S0009912020303155"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2020.06.001","relation":{},"ISSN":["0009-9120"],"issn-type":[{"type":"print","value":"0009-9120"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Soluble urokinase plasminogen activator receptor (suPAR) is lower in disease-free patients but cannot rule out incident disease in patients with suspected cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2020.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc. on behalf of The Canadian Society of Clinical Chemists.","name":"copyright","label":"Copyright"}]}}